GrzegorzSNowakowskiMD

PubMed

• Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance.
  Allison M Bock, Kerstin Wenzl, Joseph P Novak, Matthew E Stokes, Melissa A Hopper
  Hematological Oncology. 2025-01-01
• 1 citations
  Characteristics and outcomes of incidentally diagnosed diffuse large B-cell lymphoma and implications for cancer screening.
  Suheil Albert Atallah-Yunes, Matthew J Rees, Raphael Mwangi, Robyn L Kuchler, Grzegorz S Nowakowski
  American Journal of Hematology. 2025-01-01
• 5 citations
  DLBCL: who is high risk and how should treatment be optimized?
  Anna Dabrowska-Iwanicka, Grzegorz S Nowakowski
  Blood. 2024-12-19

Journal Articles

• Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia  
  Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature

Abstracts/Posters

• Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients...
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Subgroup Analyses of Elderly Patients Aged _ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo...
  Grzegorz Nowakowsk, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patie...
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Tria...
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era
  Grzegorz Nowakowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Friday Scientific Workshop on Innovation in Clinical Trials Design 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R2-CHOP in subjects with previously untreated, high-risk DLBCL. 
  2019 ASCO Annual Meeting - 6/1/2019
• Development of a Hematology-Specific Fellowship Curriculum for Advanced Practice Providers Utilizing a Needs-Based Assessment 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial ... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all